Atossa Therapeutics Appoints Financial Executive Jonathan Finn to its Board of Directors
November 09 2023 - 9:00AM
Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage
biopharmaceutical company developing innovative medicines in areas
of significant unmet medical need in oncology with a focus on
breast cancer, today announced that Jonathan Finn, CFA, has been
appointed to Atossa’s board of directors, effective November 8,
2023. Mr. Finn has more than 25 years of experience in the
financial industry with a focus on early to mid-stage biotech and
technology companies.
Mr. Finn currently serves as Executive Vice President and Chief
Investment Officer at Vantage Consulting Group, an investment
advisory firm. In this role, he directs investment strategy, asset
allocation, manager selection and portfolio construction. Mr. Finn
is also a Founding Partner of Scientia Ventures, a manager of
venture capital funds that invest in companies targeting
computational biology and chemistry, the digitization of medicine,
digital therapies, and traditional drug development businesses at
the cutting edge of the life sciences industry.
“We are pleased to welcome Jon, who has extensive experience
working with clinical stage biotechnology companies to accelerate
growth and commercialize assets, to our board of directors,” said
Steven Quay, MD, PhD, Atossa’s President and Chief Executive
Officer. “Critical data readouts expected next year will advance
our ongoing interactions with regulatory authorities and potential
partners, which makes this the perfect time to add someone with
Jonathan’s background and network to our board.”
Mr. Finn added, “I am excited to join the Atossa Therapeutics
board and work with the other directors and members of the
leadership team to fully capitalize on the value of (Z)-endoxifen
and explore opportunities beyond the current pipeline to deliver
additional shareholder value. With four ongoing Phase 2 trials and
a strong multi-year cash position, I believe the Company is well
positioned to deliver on its vision of fundamentally changing the
breast cancer treatment paradigm. I look forward to helping them
achieve this important goal.”
Earlier in his career, Mr. Finn was a portfolio manager for the
Lindner family of mutual funds, serving as co-manager for the Small
Cap and Asset Allocation funds. He currently serves as director of
Verigraft AB, a regenerative medicine venture, Rose Pharma LLC, a
development stage specialty pain company and Solör Bioenergy
Holdings AB, a bioenergy business.
About (Z)-Endoxifen(Z)-endoxifen is the most
active metabolite of the FDA approved Selective Estrogen Receptor
Modulator (SERM), tamoxifen. Studies by others have demonstrated
that the therapeutic effects of tamoxifen are driven in a
concentration-dependent manner by (Z)-endoxifen. In addition to its
potent anti-estrogen effects, (Z)-endoxifen at higher
concentrations has been shown to target PKCβ1, a known oncogenic
protein.
Atossa is developing a proprietary oral formulation of
(Z)-endoxifen that does not require liver metabolism to achieve
therapeutic concentrations and is encapsulated to bypass the
stomach as acidic conditions in the stomach convert a greater
proportion of (Z)-endoxifen to the inactive (E)-endoxifen. Atossa’s
(Z)-endoxifen has been shown to be well tolerated in Phase 1
studies and in a small Phase 2 study of women with breast cancer.
(Z)-endoxifen is currently being studied in four Phase 2 trials:
one in healthy women with measurable breast density, one in women
diagnosed with ductal carcinoma in situ, and two other studies
including the EVANGELINE study in women with ER+/HER2- breast
cancer. Atossa’s (Z)-endoxifen is protected by three issued U.S.
patents and numerous pending patent applications.
About Atossa TherapeuticsAtossa Therapeutics,
Inc. is a clinical-stage biopharmaceutical company developing
innovative medicines in areas of significant unmet medical need in
oncology with a focus on breast cancer. For more information,
please visit www.atossatherapeutics.com
ContactEric Van ZantenVP, Investor and Public
Relations610-529-6219eric.vanzanten@atossainc.com
FORWARD LOOKING STATEMENTSThis press release
contains certain information that may constitute forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. We may identify these forward-looking
statements by the use of words such as “expect,” “potential,”
“continue,” “may,” “will,” “should,” “could,” “would,” “seek,”
“intend,” “plan,” “estimate,” “anticipate,” “believe,” “future,” or
other comparable words. Forward-looking statements in this press
release are subject to risks and uncertainties that may cause
actual results, outcomes, or the timing of actual results or
outcomes, to differ materially from those projected or anticipated,
including risks and uncertainties associated with: macroeconomic
conditions and increasing geopolitical instability; the expected
timing of releasing data; any variation between interim and final
clinical results; actions and inactions by the FDA and foreign
regulatory bodies; the outcome or timing of regulatory approvals
needed by Atossa, including those needed to continue our planned
(Z)-endoxifen trials; our ability to satisfy regulatory
requirements; our ability to regain compliance with the continued
listing requirements of the Nasdaq Stock Market; our our ability to
successfully develop and commercialize new therapeutics; the
success, costs and timing of our development activities, including
our ability to successfully initiate or complete our clinical
trials, including our (Z)-endoxifen trials; our anticipated rate of
patient enrollment; our ability to contract with third-parties and
their ability to perform adequately; our estimates on the size and
characteristics of our potential markets; our ability to
successfully defend litigation and other similar complaints and to
establish and maintain intellectual property rights covering our
products; whether we can successfully complete our clinical trial
of oral (Z)-endoxifen in women with mammographic breast density and
our trials of (Z)-endoxifen in women with breast cancer, and
whether the studies will meet their objectives; our expectations as
to future financial performance, expense levels and capital
sources, including our ability to raise capital; our ability to
attract and retain key personnel; our anticipated working capital
needs and expectations around the sufficiency of our cash reserves;
and other risks and uncertainties detailed from time to time in
Atossa’s filings with the Securities and Exchange Commission,
including without limitation its Annual Reports on Form 10-K and
Quarterly Reports on 10-Q. Forward-looking statements are presented
as of the date of this press release. Except as required by law, we
do not intend to update any forward-looking statements, whether as
a result of new information, future events or circumstances or
otherwise.
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From Apr 2024 to May 2024
Atossa Therapeutics (NASDAQ:ATOS)
Historical Stock Chart
From May 2023 to May 2024